Positive results for OncoGenex drug in early prostate cancer trial
9th Sep 2005, 02:03 GMT
Data from a phase I study of OncoGenex Technologies' OGX-011, a cancer drug found to sensitize tumours to standard therapy, suggests that the drug is well-tolerated and reduces clusterin expression in primary prostate cancers in humans.
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol